

Elizabeth C Jury

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3539443/publications.pdf>

Version: 2024-02-01

79
papers

2,950
citations

186265

28
h-index

175258

52
g-index

86
all docs

86
docs citations

86
times ranked

3860
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment strategies for Sjögren's syndrome with childhood onset: a systematic review of the literature. <i>Rheumatology</i> , 2022, 61, 892-912.	1.9	7
2	Lipid metabolism in autoimmune rheumatic disease: implications for modern and conventional therapies. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	29
3	Challenges in Implementing Cardiovascular Risk Scores for Assessment of Young People With Childhood-Onset Autoimmune Rheumatic Conditions. <i>Frontiers in Medicine</i> , 2022, 9, 814905.	2.6	5
4	Comorbidity in young patients with juvenile systemic lupus erythematosus: how can we improve management?. <i>Clinical Rheumatology</i> , 2022, 41, 961-964.	2.2	5
5	The role of cholesterol metabolism in multiple sclerosis: From molecular pathophysiology to radiological and clinical disease activity. <i>Autoimmunity Reviews</i> , 2022, 21, 103088.	5.8	7
6	Metabolomics Defines Complex Patterns of Dyslipidaemia in Juvenile-SLE Patients Associated with Inflammation and Potential Cardiovascular Disease Risk. <i>Metabolites</i> , 2022, 12, 3.	2.9	11
7	P062 COVID-19 hyperinflammation can be predicted using routine clinical laboratory markers. <i>Rheumatology</i> , 2022, 61, .	1.9	0
8	Self-perceived disease activity was the strongest predictor of COVID-19 pandemic-related concerns in young people with autoimmune rheumatic diseases, irrespective of their gender, with females reporting higher concerns. <i>Rheumatology Advances in Practice</i> , 2022, 6, rkac031.	0.7	1
9	Impact of immunogenicity on clinical efficacy and toxicity profile of biologic agents used for treatment of inflammatory arthritis in children compared to adults. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110026.	2.7	6
10	Barriers to translational research in Sjögren's syndrome with childhood onset: challenges of recognising and diagnosing an orphan rheumatic disease. <i>Lancet Rheumatology</i> , The, 2021, 3, e138-e148.	3.9	6
11	A systematic review exploring the bidirectional relationship between puberty and autoimmune rheumatic diseases. <i>Pediatric Rheumatology</i> , 2021, 19, 47.	2.1	7
12	Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE. <i>EBioMedicine</i> , 2021, 65, 103243.	6.1	23
13	Disrupted Lipid Metabolism in Multiple Sclerosis: A Role for Liver X Receptors?. <i>Frontiers in Endocrinology</i> , 2021, 12, 639757.	3.5	27
14	Serum Metabolomic Signatures Can Predict Subclinical Atherosclerosis in Patients With Systemic Lupus Erythematosus. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 1446-1458.	2.4	26
15	LXR directly regulates glycosphingolipid synthesis and affects human CD4+ T cell function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	18
16	Targeting human Acyl-CoA:cholesterol acyltransferase as a dual viral and T cell metabolic checkpoint. <i>Nature Communications</i> , 2021, 12, 2814.	12.8	54
17	Biomarkers Associated with Organ-Specific Involvement in Juvenile Systemic Lupus Erythematosus. <i>International Journal of Molecular Sciences</i> , 2021, 22, 7619.	4.1	13
18	Stratification of Patients With Sjögren's Syndrome and Patients With Systemic Lupus Erythematosus According to Two Shared Immune Cell Signatures, With Potential Therapeutic Implications. <i>Arthritis and Rheumatology</i> , 2021, 73, 1626-1637.	5.6	25

#	ARTICLE	IF	CITATIONS
19	Machine Learning Techniques for Personalised Medicine Approaches in Immune-Mediated Chronic Inflammatory Diseases: Applications and Challenges. <i>Frontiers in Pharmacology</i> , 2021, 12, 720694.	3.5	37
20	Sex hormones drive changes in lipoprotein metabolism. <i>IScience</i> , 2021, 24, 103257.	4.1	21
21	Predicting long-term cardiometabolic risk: Do childhood metabolomic signatures hold the key?. <i>EBioMedicine</i> , 2021, 74, 103702.	6.1	2
22	Using peripheral blood immune signatures to stratify patients with adult and juvenile inflammatory myopathies. <i>Rheumatology</i> , 2020, 59, 194-204.	1.9	11
23	EP35â€fWhat do patients with lupus know about cardiovascular risk: could dietary modification be a promising therapeutic?. <i>Rheumatology</i> , 2020, 59, .	1.9	0
24	Using Serum Metabolomics to Predict Development of Anti-drug Antibodies in Multiple Sclerosis Patients Treated With IFN β . <i>Frontiers in Immunology</i> , 2020, 11, 1527.	4.8	24
25	Disease-associated and patient-specific immune cell signatures in juvenile-onset systemic lupus erythematosus: patient stratification using a machine-learning approach. <i>Lancet Rheumatology</i> , The, 2020, 2, e485-e496.	3.9	52
26	P122â€f...What do patients with lupus and SjÃ¶grenâ€™s syndrome know about cardiovascular risk?. , 2020, , .		0
27	P126â€f...Tolerability, efficacy and adherence: what do lupus patients think about treatment?. , 2020, , .		0
28	COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. <i>Lancet Rheumatology</i> , The, 2020, 2, e594-e602.	3.9	200
29	Clinicogenomic factors of biotherapy immunogenicity in autoimmune disease: A prospective multicohort study of the ABIRISK consortium. <i>PLoS Medicine</i> , 2020, 17, e1003348.	8.4	31
30	Editorial: Immunogenicity of Proteins Used as Therapeutics. <i>Frontiers in Immunology</i> , 2020, 11, 614856.	4.8	14
31	E024â€fInvariant natural killer T cells in RA and CVD. <i>Rheumatology</i> , 2019, 58, .	1.9	0
32	E084â€fValidation of complex immunophenotyping stratification of patients with lupus and SjÃ¶grenâ€™s syndrome with therapeutic potential. <i>Rheumatology</i> , 2019, 58, .	1.9	0
33	E089â€fCardiovascular disease in SLE: what do patients think about using diet as a therapeutic?. <i>Rheumatology</i> , 2019, 58, .	1.9	0
34	E083â€fDesigning a diet interventional study for autoimmune rheumatic disease: asking patients what they think. <i>Rheumatology</i> , 2019, 58, .	1.9	1
35	Characterization of a Subset of Patients With Rheumatoid Arthritis for Whom Current Management Strategies are Inadequate. <i>ACR Open Rheumatology</i> , 2019, 1, 145-155.	2.1	3
36	Analyzing T-Cell Plasma Membrane Lipids by Flow Cytometry. <i>Methods in Molecular Biology</i> , 2019, 1951, 209-216.	0.9	12

#	ARTICLE	IF	CITATIONS
37	Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1140-1142.	0.9	40
38	ABO229â€¦RELATIVE MONOCYTE SUBSET DIFFERENCES BETWEEN JUVENILE- AND ADULT-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
39	THU0722-HPRâ€¦DESIGNING A DIET INTERVENTIONAL STUDY FOR AUTOIMMUNE RHEUMATIC DISEASE: ASKING PATIENTS WHAT THEY THINK. , 2019, , .		0
40	THU0723-HPRâ€¦WHAT DO SJÃ–GRENâ€™S SYNDROME PATIENTS THINK ABOUT RESEARCH?. , 2019, , .		0
41	O37â€¦Complex immunophenotyping stratifies patients with primary and secondary SjÃ–grenâ€™s syndrome into distinct clinically relevant groups with potential therapeutic implications. <i>Rheumatology</i> , 2018, 57, .	1.9	0
42	Low Percentage of Signal Regulatory Protein $\hat{1}\pm/\hat{1}^2+$ Memory B Cells in Blood Predicts Development of Anti-drug Antibodies (ADA) in Adalimumab-Treated Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , 2018, 9, 2865.	4.8	9
43	O30â€¦The immunopathogenesis of juvenile-onset SLE could be associated with altered immune cell plasma membrane lipids and lipoprotein metabolism. <i>Rheumatology</i> , 2018, 57, .	1.9	0
44	254â€¦Th17 cells are increased in adult dermatomyositis: a developing immune signature for the idiopathic inflammatory myopathies. <i>Rheumatology</i> , 2018, 57, .	1.9	0
45	Monocyte NOTCH2 expression predicts IFN- $\hat{1}^2$ immunogenicity in multiple sclerosis patients. <i>JCI Insight</i> , 2018, 3, .	5.0	46
46	O26.â€¦STRATIFICATION OF PATIENTS WITH JUVENILE-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS USING IMMUNE AND METABOLIC PHENOTYPING. <i>Rheumatology</i> , 2017, 56, .	1.9	1
47	Transcriptional Regulation of T-Cell Lipid Metabolism: Implications for Plasma Membrane Lipid Rafts and T-Cell Function. <i>Frontiers in Immunology</i> , 2017, 8, 1636.	4.8	36
48	Cross-talk between iNKT cells and monocytes triggers an atheroprotective immune response in SLE patients with asymptomatic plaque. <i>Science Immunology</i> , 2016, 1, .	11.9	44
49	Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of SjÃ–grenâ€™s syndrome. <i>Rheumatology</i> , 2016, 55, 1548-1555.	1.9	63
50	Manipulating membrane lipid profiles to restore T-cell function in autoimmunity. <i>Biochemical Society Transactions</i> , 2015, 43, 745-751.	3.4	10
51	Liver X receptors in immune cell function in humans. <i>Biochemical Society Transactions</i> , 2015, 43, 752-757.	3.4	24
52	Pathogenic autoantibodies from patients with lupus nephritis cause reduced tyrosine phosphorylation of podocyte proteins, including tubulin. <i>Lupus Science and Medicine</i> , 2014, 1, e000013.	2.7	5
53	Normalizing glycosphingolipids restores function in CD4+ T cells from lupus patients. <i>Journal of Clinical Investigation</i> , 2014, 124, 712-724.	8.2	130
54	Invariant natural killer T cells are enriched at the site of cutaneous inflammation in lupus erythematosus. <i>Journal of Dermatological Science</i> , 2013, 71, 22-28.	1.9	22

#	ARTICLE	IF	CITATIONS
55	Lipid-Antigen Presentation by CD1d+ B Cells Is Essential for the Maintenance of Invariant Natural Killer T Cells. <i>Immunity</i> , 2012, 36, 477-490.	14.3	174
56	Distinct localization of Tâ€fcell Agrin during antigen presentationâ€fâ€“â€fevidence for the expression of Agrin receptor(s) in antigenâ€presenting cells. <i>FEBS Journal</i> , 2012, 279, 2368-2380.	4.7	9
57	A negatively charged domain of LAT mediates its interaction with the active form of Lck. <i>Molecular Membrane Biology</i> , 2011, 28, 487-494.	2.0	14
58	Primary Human CD4+ T Cells Have Diverse Levels of Membrane Lipid Order That Correlate with Their Function. <i>Journal of Immunology</i> , 2011, 186, 3505-3516.	0.8	71
59	Abnormal CTLAâ€4 function in T cells from patients with systemic lupus erythematosus. <i>European Journal of Immunology</i> , 2010, 40, 569-578.	2.9	50
60	Could the expression of CD86 and FcÎ³RIIB on B cells be functionally related and involved in driving rheumatoid arthritis?. <i>Arthritis Research and Therapy</i> , 2010, 12, 133.	3.5	6
61	New role for Agrin in T cells and its potential importance in immune system regulation. <i>Arthritis Research and Therapy</i> , 2010, 12, 205.	3.5	16
62	Lipid rafts and Tâ€lymphocyte function: Implications for autoimmunity. <i>FEBS Letters</i> , 2008, 582, 3711-3718.	2.8	75
63	Defects in CTLA-4 are associated with abnormal regulatory T cell function in rheumatoid arthritis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 19396-19401.	7.1	244
64	Agrin Signalling Contributes to Cell Activation and Is Overexpressed in T Lymphocytes from Lupus Patients. <i>Journal of Immunology</i> , 2007, 179, 7975-7983.	0.8	12
65	Lipid rafts in T cell signalling and disease. <i>Seminars in Cell and Developmental Biology</i> , 2007, 18, 608-615.	5.0	115
66	Altered lipid raftâ€associated proximal signaling and translocation of CD45 tyrosine phosphatase in B lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2007, 56, 291-302.	6.7	44
67	Atorvastatin Restores Lck Expression and Lipid Raft-Associated Signaling in T Cells from Patients with Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2006, 177, 7416-7422.	0.8	114
68	Decreased Lyn expression and translocation to lipid raft signaling domains in B lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 52, 3955-3965.	6.7	114
69	Statins: immunomodulators for autoimmune rheumatic disease?. <i>Lupus</i> , 2005, 14, 192-196.	1.6	31
70	Statins for Atherosclerosis â€” As Good as It Gets?. <i>New England Journal of Medicine</i> , 2005, 352, 73-75.	27.0	125
71	T-lymphocyte signalling in systemic lupus erythematosus: a lipid raft perspective. <i>Lupus</i> , 2004, 13, 413-422.	1.6	24
72	Atorvastatin Inhibits Autoreactive B Cell Activation and Delays Lupus Development in New Zealand Black/White F1 Mice. <i>Journal of Immunology</i> , 2004, 173, 7641-7646.	0.8	113

#	ARTICLE	IF	CITATIONS
73	Regulation of T-cell receptor signalling by membrane microdomains. <i>Immunology</i> , 2004, 113, 413-426.	4.4	89
74	Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2004, 113, 1176-1187.	8.2	156
75	Altered lipid raft-associated signaling and ganglioside expression in T lymphocytes from patients with systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 2004, 113, 1176-1187.	8.2	98
76	Increased ubiquitination and reduced expression of LCK in T lymphocytes from patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003, 48, 1343-1354.	6.7	80
77	Autoantibodies and overlap syndromes in autoimmune rheumatic disease. <i>Journal of Clinical Pathology</i> , 2001, 54, 340-347.	2.0	53
78	Sex Differences in Lipid Metabolism: Implications for Systemic Lupus Erythematosus and Cardiovascular Disease Risk. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	4
79	CD8+ T-Cells in Juvenile-Onset SLE: From Pathogenesis to Comorbidities. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	0